These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26313418)

  • 1. Drug transporters in breast cancer: response to anthracyclines and taxanes.
    Kümler I; Stenvang J; Moreira J; Brünner N; Nielsen DL
    Expert Rev Anticancer Ther; 2015; 15(9):1075-92. PubMed ID: 26313418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone for the treatment of breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
    Chien AJ; Moasser MM
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PubMed ID: 18410794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.
    Rivera E
    Breast J; 2010; 16(3):252-63. PubMed ID: 20408828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of breast cancer resistance to anthracyclines or taxanes: an overview of the proposed roles of noncoding RNA.
    Li XJ; Zha QB; Ren ZJ; Tang JH; Yao YF
    Curr Opin Oncol; 2015 Nov; 27(6):457-65. PubMed ID: 26371779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
    Perez EA
    Breast Cancer Res Treat; 2009 Mar; 114(2):195-201. PubMed ID: 18443902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
    Hembruff SL; Laberge ML; Villeneuve DJ; Guo B; Veitch Z; Cecchetto M; Parissenti AM
    BMC Cancer; 2008 Nov; 8():318. PubMed ID: 18980695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming taxane and anthracycline resistance.
    Zelnak A
    Breast J; 2010; 16(3):309-12. PubMed ID: 20408821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
    Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
    J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.
    Wang S; Qiu J; Shi Z; Wang Y; Chen M
    Biotechnol Adv; 2015; 33(1):224-241. PubMed ID: 25447422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer.
    Rincón R; Zazo S; Chamizo C; Manso R; González-Alonso P; Martín-Aparicio E; Cristóbal I; Cañadas C; Perona R; Lluch A; Eroles P; García-Foncillas J; Albanell J; Rovira A; Madoz-Gúrpide J; Rojo F
    Mol Cancer Ther; 2016 Nov; 15(11):2780-2790. PubMed ID: 27599524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using specific cytotoxics with a targeted mind.
    Di Leo A; Claudino WM; Pestrin M; Licitra S; Biganzoli L
    Breast; 2007 Dec; 16 Suppl 2():S120-6. PubMed ID: 17720501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).
    Fojo AT; Menefee M
    Semin Oncol; 2005 Dec; 32(6 Suppl 7):S3-8. PubMed ID: 16360716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.